150,000 Orion A-shares converted into B-shares
October 25, 2013 - London
ORION CORPORATIONSTOCK EXCHANGE RELEASE 25 OCTOBER 2013 at 9.20 a.m. EEST
In accordance with Section 3 of the Articles of Association of Orion Corporation, 150,000 A-shares have been converted into 150,000 B-shares. The conversion has been entered into the Trade Register on 25 October 2013.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 42,022,816 A-shares and 99,235,012 B-shares.
| Olli Huotari|
SVP, Corporate Functions
| Jari Karlson|
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Orion Oyj via Thomson Reuters ONE